BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 30, 2009
View Archived Issues
Nitazoxanide increases early virological response rates in genotype 1 HCV patients
Read More
Neuren and the BCRT establish new company to target breast and other cancers
Read More
Experiments characterize CKD-516, a novel anticancer tubulin-binding agent
Read More
Saxagliptin improves glycemic control in diabetic patients as add-on or combination therapy
Read More
Olesoxime appears safe in spinal muscular atrophy patients
Read More
AEZS-112 safe, well tolerated in phase I trial in advanced cancer and lymphoma patients
Read More
Roche claims novel glucocorticoid receptor antagonists as antidiabetic agents
Read More
Servier presents novel compounds for the treatment of cardiovascular conditions
Read More
EMD-521873 shows safety in phase I trial in patients with advanced solid tumors
Read More
Novel antitumor compounds claimed by Merck & Co.
Read More
Novel oxadiazole derivatives for the treatment of autoimmune diseases claimed by Merck Serono
Read More
Aeras and Crucell initiate TB vaccine study in South African infants
Read More
Histone deacetylase inhibitors described by Merck & Co. for cancer treatment
Read More
BI-207127 monotherapy shows promising anti-hepatitis C virus genotype 1 activity in phase I trial
Read More
Cougar initiates phase III CB-7630 trial in castration-resistant prostate cancer
Read More
FDA grants orphan drug designation to Oncophage for glioma
Read More
FDA grants priority review to Xiaflex filing for Dupuytren's contracture
Read More
Genaera to liquidate assets and dissolve the company
Read More
Oxford BioMedica and sanofi-aventis to develop LentiVector-based ophthalmology drugs
Read More
Oxford BioMedica regains worldwide rights to cancer vaccine TroVax from sanofi-aventis
Read More
Alnylam and Isis sign licensing and collaboration agreement to develop ssRNAi technology
Read More
Enrollment completed in Rockwell Medical's phase IIb study of SFP in iron deficiency anemia
Read More
Genta provides update for late-stage progress of phase III Genasense trial
Read More
Stallergenes reports positive results from a phase IIb/III clinical trial
Read More
FDA approves BLA for Ipsen's Dysport in cervical dystonia and glabellar lines
Read More
ImQuest and Arisyn sign agreement to develop infectious disease and cancer drugs
Read More